<DOC>
	<DOCNO>NCT00314912</DOCNO>
	<brief_summary>The purpose Phase III open-label extension study evaluate long-term safety Tramiprosate ( 3APS ) patient mild moderate Alzheimer â€™ disease .</brief_summary>
	<brief_title>Open-Label Extension Phase III Study With Tramiprosate ( 3APS ) Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Duration treatment : 12 month . Patients complete Phase III clinical trial offer opportunity receive Tramiprosate ( 3APS ) open-label extension study</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Tramiprosate</mesh_term>
	<criteria>The patient must successfully complete full 78week duration doubleblind CL758007 study . Male female ( age 50 year old ) : Female must nonchildbearing potential ( i.e . surgically sterilize least 2 year postmenopausal ) . Patient must live community reliable caregiver . Participant living assist living facility may include study medication intake supervise participant reliable caregiver . The patient must present reasonably good nutritional status . Signed inform consent patient legal representative . Patients eligible participate study meet follow criterion : The patient participate another drug trial study . The patient clinically significant and/or uncontrolled condition significant medical disease . The patient unable swallow medication tablet .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>